
Arcus Biosciences, Inc.
RCUSNYSECIK 1724521HealthcareFiscal year ends Dec 31
Reports and events: 148 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-01-3008:17 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001724521-24-000034 |
| 2023-11-0716:11 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001724521-23-000021 |
| 2023-11-0716:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001724521-23-000018 |
| 2023-08-0708:13 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-038760 |
| 2023-08-0708:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-038757 |
| 2023-06-2808:25 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0000950170-23-030273 |
| 2023-06-1616:19 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-028621 |
| 2023-06-0508:25 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0000950170-23-026241 |
| 2023-05-1508:34 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-23-021988 |
| 2023-05-0916:15 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-019695 |
| 2023-05-0916:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-019659 |
| 2023-04-2116:09 ET | DEF 14A | Proxy statement | 0000950170-23-013840 |
| 2023-03-1016:46 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-007320 |
| 2023-02-2816:18 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-005112 |
| 2023-02-2816:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-005084 |
| 2022-12-1917:05 ET | 8-K | 8.01 Other events | 0000950170-22-026760 |
| 2022-11-2808:39 ET | 8-K | 8.01 Other events | 0000950170-22-025712 |
| 2022-11-0216:11 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-021241 |
| 2022-11-0216:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-021219 |
| 2022-10-1116:13 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-22-260620 |
| 2022-08-0316:22 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-014280 |
| 2022-08-0316:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-014263 |
| 2022-06-1616:14 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-22-011747 |
| 2022-05-0916:15 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008502 |
| 2022-05-0916:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-008484 |
| 2022-04-2016:12 ET | DEF 14A | Proxy statementPeriod 2022-06-14 | 0000950170-22-005855 |
| 2022-02-2316:16 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-001788 |
| 2022-02-2316:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-001777 |
| 2021-12-2116:40 ET | 8-K | 8.01 Other events | 0000950170-21-005305 |
| 2021-11-1807:06 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-21-004749 |
| 2021-11-0817:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-003506 |
| 2021-11-0816:16 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-003471 |
| 2021-08-1116:33 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-043472 |
| 2021-08-0516:19 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-041611 |
| 2021-08-0516:13 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001564590-21-041591 |
| 2021-07-1916:47 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001564590-21-037042 |
| 2021-06-0716:26 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001564590-21-031965 |
| 2021-05-0516:19 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-024084 |
| 2021-05-0516:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-024065 |
| 2021-04-2616:24 ET | 8-K | 7.01 Regulation FD disclosure | 0001564590-21-020541 |
| 2021-04-2016:09 ET | DEF 14A | Proxy statementPeriod 2021-06-03 | 0001564590-21-019630 |
| 2021-04-1919:02 ET | 8-K | 3.01 Delisting notice | 0001564590-21-019230 |
| 2021-03-1616:06 ET | 8-K | 8.01 Other events | 0001564590-21-013565 |
| 2021-02-2519:10 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-008270 |
| 2021-02-2416:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-008094 |
| 2021-02-0108:08 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001564590-21-003492 |
| 2021-01-0616:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-000408 |
| 2020-12-1816:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001564590-20-057677 |
| 2020-11-0516:25 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001564590-20-051355 |
| 2020-11-0516:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-051327 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 4, 2026, 17:06 ET. Listed shows no prices and gives no investment advice.